drugset

Drugs / Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

Follow last change Feb 2021 re-read 3 minutes ago

Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

Developed for: COVID-19
Investigated by: CanSino Biologics Inc. · Hubei Provincial Center for Disease Control and Prevention · Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China · Jiangsu Province Centers for Disease Control and Prevention · Tongji Hospital

Trials 1

today NCT04313127 · Ph 1

202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 11 trial
Phase 1	NCT04313127	Mar 2020 → Jan 2021	COVID-19	CanSino Biologics Inc.	Completed	No outcome recorded
Comparator or background therapy1 trial
Phase 2	NCT04341389 Comparator	Apr → Nov 2020	COVID-19	Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China	Completed	No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04341389 ↗ 1 NCT04313127 ↗
Modality	Vaccine	“Ad5 vectored COVID-19 vaccine” PMID 32450106 ↗ May 2020
Route	Intramuscular	“intramuscular injection of vaccine” PMID 32450106 ↗ May 2020